Welcome to Blood Cancer United Newsroom
Get the latest news about how we are creating a world without blood cancers—and improving the quality of life of patients and their families.
News
FDA Approves New Type of BTK Inhibitor to Treat Mantle Cell Lymphoma
The U.S. Food and Drug Administration today approved pirtobrutinib (Jaypirca™), the first non-covalent, reversable BTK inhibitor for the treatment of …
Research
Encouraging Additional Data for Bexmarilimab for the Treatment of Hematological Malignancies
January 16, 2023 - TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company …
Research
BioInvent Selected to The Leukemia & Lymphoma Society’s Therapy Acceleration Program and Receives $3 Million Strategic Equity Investment
Lund, Sweden – January 17, 2023 – BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and de…
News
Insured Cancer Patients Continue to Face Barriers To Medically Necessary Treatment, New Report Warns
The new report published by The Leukemia & Lymphoma Society and Manatt Health offers concrete policy solutions.
Research
Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009
WALTHAM, Mass., January 4, 2023 – Immunitas Therapeutics (“Immunitas”), a clinical stage precision immunotherapy company committed to discovering and …
Research
Apply to the Influential Medicine Providing Access to Clinical Trials (IMPACT) Program
Expanding access to high-quality clinical trials to patients served by community health settings, particularly rural, minority, and/or economically di…
For all media-related inquiries and interview requests please email
mediarelations@bloodcancerunited.org
A Blood Cancer United representative will respond as soon as possible.
